PTO/SB/088 (08-00)
Approved for use through 10/31/2002 OMB 0551-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

United the Paparwork Reduction Act of 1835; the persons are requ	reduces to respond to a consecution among dates a contraint a value Owe control number			
	Complete if Kn wn			
Substitute for Form 1449/A/PTO	Application Number	Unassigned 10 796,691		
INFORMATION DISCLOSURE	Filing Date	Herewith		
	First Named Inv ntor	Marc BELLOTTI et al.		
STATEMENT BY APPLICANT	Group Art Unit	Unassigned 1653		
(use as many sheets as necessary	Examiner Name	Unassigned Robert Monden.		
Sheet A of A	Attorney Docket Number	13131-0331 (44378/293531)		

		OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No."	Include name of the author (in CAPITAL LETTERS), little of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T2
RN	20. BARRANS, ALAIN, et al., *Pre-β HDL: Structure and Metabolism,* Biochimica et Biophysica Acta 1300, pp. 73-85, (1996).		
-	21. CRUZADO, INGRID D., et al., "Characterization and Quantitation of the Apoproteins of High-Density Lipoprotein by Cap		
PBS		Electrophoresis," Analytical Biochemistry, 243, Article No. 0487, pp. 100-109 (1996).	
,	22.	HATCH, FREDERICK T., et al., "Practical Methods for Plasma Lipoprotein Analysis," Plasma Lipoprotein Analysis, Advances	
\		in Lipid Research, 6: pp. 1-68 (1968).	
	23.	JACKSON, RICHARD L., et al., "Isolation and Characterization of the Major Apolipoprotein from Chicken High Density	
		Lipoproteins,* Biochimica et Biophysica Acta, 420, pp. 342-349 (1976).	
	24.	MOYA, M. de la LLERA, et al., "A Cell Culture System for Screening Human Serum for Ability to Promote Cellular Cholesterol	
		Efflux," Arteriosclerosis and Thrombosis, Vol. 14, No. 7, pp. 1056-1065, (July 1994).	
	25.	OKAZAKI, MITSUYO, et al., "Improved High-Performance Liquid Chromatographic Method for the Determination of	
		Apolipoproteins in Serum High-Density Upoproteins," Journal of Chromatography, Biomedical Applications, 430, pp. 135-142	
		(1988).	
	26.	ROBERN, H., "The Application of Sodium Deoxycholate and Sephacryl-200 for the Delipidation and Separation of High	
		Density Lipoprotein," Experientia, 38, pp. 437-439 (1982).	
	27.	RUOCCO, PATERNO, R., et al., "Reconstituted High-Density Lipoprotein Exhibits Neuroprotection in Two Rat Models of	
. }		Stoke," Department of Clinical and Experimental Medicine, University 'Federico II', Naples Italy, Ed Bertotas Associates, Inc.	
	28.	SCANU, A.M., et al., "Solubility in Aqueous Solutions of Ethanol of the Small Molecular Weight Peptides of the Serum Very	
-1		Low Density and High Density Lipoproteins: Relevance to the Recovery Problem During Delipidation of Serum Lipoproteins,*	
		Analytical Biochemistry, 44, pp. 576-588 (1971).	
\dashv	29.	SEGREST, JERE P., et al., "A Detailed Molecular Belt Model for Apolipoprotein A-I in Discoidal High Density Lipoprotein," The	
		Journal of Biological Chemistry, Vol. 274, No. 45, pp. 31755-31758, Issue of November 5, 1999.	
	30.	WILLIAMS, K.J., et al., "Uptake of Endogenous Cholesterol by a Synthetic Lipoprotein," Biochim. Biophys. Acta, 875(2), pp.	
.		183-194 (February 12, 1986).	
	31.	WORMSER, HENRY, Ph.D., "Lipids," PSC 3110, Fall Semester 2002.	<u> </u>
	32.	ZHANG, WENWU, et al., *Characterization of Phospholipids in pre-a HDL: Selective Phospholipid Efflux with Apolipoprotein A-	
+		I," Journal of Lipid Research, Volume 39, pp. 1601-1607 (1998).	

niner ature	Robert B. 1	, Land	Date Considered	1-10-05

¹Unique ditation designation number. ²Applicant is to place a check mark here if English language translation is attached.

PTO/SB/08B (08-00) Approved for use through 10/31/2002 OMB 0851-0031

NOV 0 9 2005 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Paperwork Reduction of 1895, no persons are required to respond to a collection of information unless it contains a valid OMB control Under number

Substitute for Form ASSAFTO				Complete if Known			
Substitute	for Former Property	ſÓ		Application Number	10/796,691		
INIE	ODBAATI	ON.	DISCLASURE	Filing Date	March 8, 2004		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				First Named Inventor	BELLOTTI, Marc		
			Y APPLICANT	Group Art Unit	1653		
	(use as mai	ny sher	ats as necessary	Examiner Name	Mondesi, Robert B.		
Sheet	1	of	2	Attorney Docket	13131-0331 (44378/293531)		

Number **U.S. PATENT DOCUMENTS** Name of Patentee or Applicant of Cited Document **Document Number** Publication Date MM-DD-YYYY Cite No.* Pages, Columns, Lines, Where Relevant Examiner Passages or Relevant Figures Appear Initials * Number - Kind Code² (# known) 06-25-1998 US-5,529,933 Young et al 1 US-US-US-US-US-US-US-US-US. US-US-US-USus-US-US-US-US-US-

		FOREIGN PA	TENT DOCU	MENTS		
Fuerrises	Cite	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines, Where Relevant	
Examiner Initials*	No.'	Country Code ³ - Number ⁴ - Kind Code ⁵ (<i>if known</i>)	Date MM-DD-YYYY	Applicant of Cited Document	Passages or Relevant Figures Appear	T⁰
	 -					
	 					
	 					

Examiner Signature	Rober S Monda:	Date Considered	3-27-06

"EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 'Enter Office that Issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.' 'Kind of document by the appropriate symbols as Indicated on the document under WIPO Standard ST. 16 if possible.' Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.

This collection of Information is required by 37 CFR 1.97 and 1.98. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-00)

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary

Sheet 2 of 2

Cor	nplete if Known		
Application Number 10/796,691			
Filing Date March 8, 2004			
First Named Inventor BELLOTTI, Marc			
Group Art Unit 1653			
Examiner Name Mondesi, Robert B.			
Attorney Docket Number	13131-0331 (44378/293531)		

		OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
	2	BLANCHE, PATRICIA J., et al., "Characterization of Complexes of Egg Yolk Phosphatidylcholine and Apolipoprotein A-II	
80		Prepared in Absence and Presence of Sodium Cholate*, Biochimica et Biophysica Acta, 1988, pp. 143-152, Vol. 958.	
	3	DURBIN, DIANE M. et al., "The Effect of Apolipoprotein A-II on the Structure and Function of Apolipoprotein A-I in a	
		Homogeneous Reconstituted High Density Lipoprotein Particle*, The Journal of Biological Chemistry, 1997, pp. 31333-31339, Vol. 272, No. 50.	
-	4	MATZ, CHARLES E. et al., "Reaction of Human Lecithin Cholesterol Acyltransferase with Synthetic Micellar Complexes of	_
		Apolipoprotein A-I, Phosphatidylcholine, and Cholesterol*, The Journal of Biological Chemistry, 1982, pp. 4541-4546, Vol. 257,	
		No. 8.	
1	5	NISSEN, STEVEN E., et al. "Effect of Recombinant ApoA-1 Milano on coronary Atherosclerosis in Patients with Acute	
		Coronary Syndromes", Journal of American Medical Association", 2003, pp. 2292-2300, Vol. 290, No. 17.	
	6	OSBORNE, JAMES C. et al., "Delipidation of Plasma Lipoproteins", Methods in Enzymology, 1986, pp. 213-222, Vol. 128.	
- 	7	RYE, KERRY-ANNE, et al. "Changes in the Size of Reconstituted High Density Lipoproteins During Incubation with	
1		Cholesteryl Ester Transfer Protein: the Role of Apolipoproteins*, 1992, pp. 215-224, Vol. 33.	
			<u> </u>
			ļ
			ļ
			<u> </u>
			<u> </u>
			<u> </u>
		·	
			_

Examiner Signature	Pohad B. Madai	Date Considered	3-27-06
Signature	70000	Considered	